TOX/2025/47 Annex A

Abbreviations

TOX/2025/47

Last updated: 05 December 2025

This is a background paper for discussion. It has not been finalised and should not be cited.

AKT

Protein kinase B

Anti-OVA

Anti-ovalbumin

AOP

Adverse outcome pathway

APROBA

Approximate probabilistic analysis (tool)

BMD

Benchmark dose

BMDL

Lower confidence level of the benchmark dose

BMDR

Benchmark dose response

BPA

Bisphenol A

BPS

Bisphenol S

bw

Bodyweight

DMA

Dimethacrylate

DNA

Deoxyribonucleic acid

DNELs

Derived no effect levels

ERRɣ

Estrogen-related receptor gamma

FCM

Food Contact Materials

GLP

Good laboratory practise

HBGV

Health based guidance value

HED(F)      

Human equivalent dose (factor)

IFN-ɣ

Interferon gamma

IgA

Immunoglobulin A

IL-17/21/6/23/4/3

Interleukin-17/21/6/23/4/3

LOAEL

Lowest observed adverse effect level

MLN

Mesenteric lymph nodes

MoA

Mode of action

NOAEL

No observed adverse effect level

OEL

Occupational exposure limit

PC        

Polycarbonates

PI3K

Phosphatidylinositol 3-kinase

POD

Point of departure

RP

Reference point

SLE

Systemic lupus erythematosus

SML

Specific migration limit

t-TDI

Temporary tolerable daily intake

TNF-α

Tumour necrosis factor alpha

UF

Uncertainty factor

WoE

Weight of evidence

BfR

German Federal Institute for Risk Assessment

CEP

EFSA Panel on Food Contact Materials, Enzymes and Processing Aids

COT

Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment

EC

European Commission

ECHA

European Chemicals Agency

EFSA

European Food Safety Authority           

EFSA CEP Panel

EFSA’s Panel on Food Contact Materials, Enzymes and Processing Aids

EMA

European Medical Agency

EU

European Union

FDA

United States Food and Drug Administration

IPCS

International Programme on Chemical Safety

OECD

Organisation for Economic Co-operation and Development

UK

United Kingdom

WHO

World Health Organisation